Zynerba Pharmaceuticals (ZYNE) earnings: expect 47% EPS growth

6:45 pm ET, 08 May 2019

Zynerba Pharmaceuticals (ZYNE) is announcing earnings on May 14. We combed through analyst estimates to understand what the company revenue and earnings are predicted to look like.

What should you expect from the upcoming earnings?

Earnings per share are expected to come in at $-0.48. If this materializes, EPS will grow 47% year-over-year.

How did the stock do last month?

Over the last month, Zynerba Pharmaceuticals (ZYNE) returned +54.73%.

What do analysts say about the stock?

Zynerba Pharmaceuticals (ZYNE) average analyst price target is 30.4% above its current price ($12.50).

For the latest price and information on Zynerba Pharmaceuticals, please visit Finstead and ask for "ZYNE", "ZYNE analysis" or "ZYNE news".

Powered by Froala Editor

Zynerba Pharmaceuticals, Inc. (ZYNE) Stock Guide

Updated at: 9:25 pm ET, 18 Sep 2020

Before we start: if you're looking for ZYNE stock price, you can quickly find it out by visiting Finny and typing "ZYNE quote". If you're looking for a quick scoop on ZYNE stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "ZYNE". You'll get all this info in one place. Or you can just type "ZYNE news" to get the latest stock news.

Looking to buy or sell Zynerba Pharmaceuticals, Inc. (ZYNE)? Interested in getting the full scoop on ZYNE, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this ZYNE stock guide, we'll address key questions about ZYNE, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are ZYNE earnings?
2. What is ZYNE stock forecast (i.e., prediction)?
3. ZYNE buy or sell? What is ZYNE Finny Score?
4. What are the reasons to buy ZYNE? Why should I buy ZYNE stock?
5. What are the reasons to sell ZYNE? Why should I sell ZYNE stock?
6. What are ZYNE key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are ZYNE earnings?

ZYNE trailing 12-month earnings per share (EPS) is -$1.89.

Analyst Predictions

2. What is ZYNE stock forecast (i.e., prediction)?

Based on ZYNE analyst price targets, ZYNE stock forecast is $10.00 (for a year from now). That means the average analyst price target for ZYNE stock is $10.00. The prediction is based on 7 analyst estimates.

The low price target for ZYNE is $4.50, while the high price target is $15.00.

ZYNE analyst rating is Buy.

Analysis

3. ZYNE buy or sell? What is ZYNE Finny Score?

#{finnyScore:60}Our quantitative analysis shows 3 reasons to buy and 2 reasons to sell ZYNE, resulting in Finny Score of 60.

4. What are the reasons to buy ZYNE? Why should I buy ZYNE stock?

Here are the reasons to buy ZYNE stock:

  • Phase 2/3 clinical trial evaluating ZYN002, a cannabinoid transdermal gel, is looking optimistic for patients with Fragile X syndrome.
  • Although still not revenue generating, the company has enough cash to sustain its operations for at least another 18 months.
  • ZYNE average analyst rating is Buy. See ZYNE analyst rating chart.
  • ZYNE average analyst price target ($10.00) is above its current price ($3.70). See ZYNE price target chart.
  • ZYNE cash to debt ratio is 324.36, higher than the average industry (0.16) and sector (0.16) cash to debt ratio. See ZYNE cash to debt chart.

5. What are the reasons to sell ZYNE? Why should I sell ZYNE stock?

Let's look at the reasons to sell ZYNE stock (i.e., the bear case):

  • ZYNE short share of float is 19.74%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock. See ZYNE short share of float chart.
  • ZYNE short interest (days to cover the shorts) ratio is 7.04. The stock garners more short interest than the average industry, sector or S&P 500 stock. See ZYNE short interest ratio chart.

Key Stats

6. What are ZYNE key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for ZYNE:

Metrics ZYNE
Price $3.69
Average Price Target / Upside $10.00 / 170.64%
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 25
Market Cap $104.44M
Forward P/E Ratio -2.25
Price/Book Ratio N/A
Revenue (TTM) N/A
YoY Quarterly Revenue Growth N/A
Profit Margin 0.00%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us